MX2019009954A - Metodos para el tratamiento de pacientes con neoplasias malignas hematologicas. - Google Patents
Metodos para el tratamiento de pacientes con neoplasias malignas hematologicas.Info
- Publication number
- MX2019009954A MX2019009954A MX2019009954A MX2019009954A MX2019009954A MX 2019009954 A MX2019009954 A MX 2019009954A MX 2019009954 A MX2019009954 A MX 2019009954A MX 2019009954 A MX2019009954 A MX 2019009954A MX 2019009954 A MX2019009954 A MX 2019009954A
- Authority
- MX
- Mexico
- Prior art keywords
- present disclosure
- methods
- wild
- treating patients
- further relates
- Prior art date
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 title 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- -1 2,3-dihydro-isoindole-1-one compound Chemical class 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción comprende un método para administrar el compuesto 2,3-dihidro-isoindol- 1-ona o una sal, éster, solvato y/o profármaco farmacéuticamente aceptable de este, para el tratamiento de cánceres hematológicos, tal como leucemia mieloide aguda (LMA). La presente descripción se refiere, además, a reducir o inhibir la proliferación celular que se activa mediante el receptor de tirosina cinasa 3 tipo Fms (FLT3) de tipo salvaje o mutada. La presente descripción se refiere, además, a un método para inhibir o reducir la actividad anómala (por ejemplo, sobreexpresión) de BTK de tipo salvaje o mutado en un sujeto que lo necesita.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461584P | 2017-02-21 | 2017-02-21 | |
| US201762578948P | 2017-10-30 | 2017-10-30 | |
| PCT/US2018/018951 WO2018156578A1 (en) | 2017-02-21 | 2018-02-21 | Methods for treating patients with hematologic malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009954A true MX2019009954A (es) | 2019-12-19 |
Family
ID=63253344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009954A MX2019009954A (es) | 2017-02-21 | 2018-02-21 | Metodos para el tratamiento de pacientes con neoplasias malignas hematologicas. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180344702A1 (es) |
| EP (1) | EP3585778A4 (es) |
| JP (2) | JP7227913B2 (es) |
| KR (1) | KR20190128646A (es) |
| CN (1) | CN110621665A (es) |
| AU (2) | AU2018225539B2 (es) |
| CA (1) | CA3054196A1 (es) |
| IL (1) | IL268736A (es) |
| MX (1) | MX2019009954A (es) |
| TW (1) | TWI821174B (es) |
| WO (1) | WO2018156578A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4219556A3 (en) | 2016-12-21 | 2023-10-11 | The United States of America as represented by The Secretary Department of Health and Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| JP2022509257A (ja) * | 2018-11-30 | 2022-01-20 | アプトース バイオサイエンシズ インコーポレイテッド | ２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| MX2021015724A (es) | 2019-06-27 | 2022-05-16 | Hanmi Pharm Ind Co Ltd | Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos. |
| AU2020370110A1 (en) * | 2019-10-21 | 2022-05-26 | Rhizen Pharmaceuticals Ag | Compositions comprising a DHODH inhibitor for the treatment of acute myeloid leukemia |
| US20240091226A1 (en) * | 2021-01-05 | 2024-03-21 | Sumitomo Pharma Oncology, Inc. | Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor |
| US11926625B2 (en) * | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| EP4370506A1 (en) | 2021-12-30 | 2024-05-22 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| EP4630122A1 (en) * | 2022-12-10 | 2025-10-15 | Aptose Biosciences Inc. | Methods for treating patients with hematologic malignancies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012047017A2 (ko) * | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 |
| PT2940014T (pt) * | 2012-12-28 | 2018-11-28 | Crystalgenomics Inc | Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo |
| US10463658B2 (en) * | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| WO2015063768A1 (en) * | 2013-10-31 | 2015-05-07 | Biokine Therapeutics Ltd. | Methods of treating acute myeloid leukemia with a flt3 mutation |
-
2018
- 2018-02-21 US US15/901,439 patent/US20180344702A1/en not_active Abandoned
- 2018-02-21 WO PCT/US2018/018951 patent/WO2018156578A1/en not_active Ceased
- 2018-02-21 JP JP2019545304A patent/JP7227913B2/ja active Active
- 2018-02-21 MX MX2019009954A patent/MX2019009954A/es unknown
- 2018-02-21 KR KR1020197027330A patent/KR20190128646A/ko not_active Ceased
- 2018-02-21 EP EP18756992.6A patent/EP3585778A4/en not_active Withdrawn
- 2018-02-21 TW TW107105790A patent/TWI821174B/zh active
- 2018-02-21 CN CN201880018924.0A patent/CN110621665A/zh active Pending
- 2018-02-21 AU AU2018225539A patent/AU2018225539B2/en active Active
- 2018-02-21 CA CA3054196A patent/CA3054196A1/en not_active Withdrawn
-
2019
- 2019-08-15 IL IL26873619A patent/IL268736A/en unknown
-
2022
- 2022-02-18 US US17/675,469 patent/US20230012148A1/en not_active Abandoned
- 2022-10-10 AU AU2022252696A patent/AU2022252696B2/en not_active Expired - Fee Related
- 2022-12-12 JP JP2022197816A patent/JP7431309B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230012148A1 (en) | 2023-01-12 |
| CA3054196A1 (en) | 2018-08-30 |
| CN110621665A (zh) | 2019-12-27 |
| EP3585778A4 (en) | 2020-12-02 |
| KR20190128646A (ko) | 2019-11-18 |
| JP7227913B2 (ja) | 2023-02-22 |
| TW201842906A (zh) | 2018-12-16 |
| AU2018225539A1 (en) | 2019-09-05 |
| JP2020508313A (ja) | 2020-03-19 |
| EP3585778A1 (en) | 2020-01-01 |
| TWI821174B (zh) | 2023-11-11 |
| AU2022252696A1 (en) | 2022-11-03 |
| JP2023022330A (ja) | 2023-02-14 |
| IL268736A (en) | 2019-10-31 |
| WO2018156578A1 (en) | 2018-08-30 |
| JP7431309B2 (ja) | 2024-02-14 |
| US20180344702A1 (en) | 2018-12-06 |
| AU2018225539B2 (en) | 2022-07-14 |
| AU2022252696B2 (en) | 2025-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009954A (es) | Metodos para el tratamiento de pacientes con neoplasias malignas hematologicas. | |
| MX2022002415A (es) | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| PH12017500146A1 (en) | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof | |
| MX2021002322A (es) | Nuevos metodos. | |
| MX393599B (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| PH12015501326A1 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer | |
| MY186126A (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| ZA202306172B (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MX2016007311A (es) | Metodos para tratar canceres. | |
| MX2022009612A (es) | Combinacion de bi853520 con farmacos quimioterapeuticos. | |
| TW201613589A (en) | Combination methods for treating cancers | |
| ZA202102438B (en) | Melflufen dosage regimens for cancer | |
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| MX2023004998A (es) | Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. | |
| PH12021552579A1 (en) | Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations | |
| MX2020010618A (es) | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. | |
| MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. | |
| PH12020551495A1 (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations | |
| MX2021011925A (es) | Compuestos con actividad antitumoral contra celulas cancerigenas que portan inserciones del exon 21 del receptor 2 del factor de crecimiento epidermico humano. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2019000413A (es) | Inhibidores de triptofano 2,3-dioxigenasa. |